| Q88851412 | ANCA Glomerulonephritis and Vasculitis |
| Q39339897 | ANCA-associated vasculitis with renal involvement |
| Q55340553 | Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy. |
| Q35836369 | Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service |
| Q47800187 | Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future? |
| Q41481664 | Clinical Trials in Vasculitis |
| Q39088103 | Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn |
| Q50069110 | Con: High-volume plasma exchange application in nephrology and beyond |
| Q41208157 | Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? |
| Q38543360 | Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients? |
| Q27025692 | Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis) |
| Q40684657 | EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. |
| Q53513595 | End-stage renal disease in ANCA-associated vasculitis. |
| Q37640836 | Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis |
| Q97590549 | Gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis |
| Q44119588 | Glomerular disease: ANCA-associated GN--to PLEX or not to PLEX? |
| Q30276550 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue |
| Q93050598 | Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist |
| Q38709517 | Hurdles to the introduction of new therapies for immune-mediated kidney diseases |
| Q33952749 | Induction monotherapy with sirolimus has selected beneficial effects on glomerular and tubulointersititial injury in nephrotoxic serum nephritis |
| Q64250361 | Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study |
| Q48937679 | Issues in trial design for ANCA-associated and large-vessel vasculitis |
| Q98735911 | Lactobacillus acidophilus Endocarditis Complicated by Pauci-Immune Necrotizing Glomerulonephritis |
| Q87829268 | Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis |
| Q37093451 | Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study |
| Q47191744 | Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial |
| Q33564565 | Lung involvement in childhood onset granulomatosis with polyangiitis |
| Q38818682 | Management of Small Vessel Vasculitides |
| Q94673520 | Narrative Review of Hypercoagulability in Small-Vessel Vasculitis |
| Q39072021 | Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. |
| Q38946711 | Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement. |
| Q89694411 | Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis |
| Q38377281 | Plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis--a 25-year perspective |
| Q41099072 | Plasmapheresis therapy in ANCA-associated vasculitides: A single-center retrospective analysis of renal outcome and mortality |
| Q58773547 | Primary Vasculitis in Childhood: GPA and MPA in Childhood |
| Q47741998 | Pro: High dose of therapeutic plasma exchange-mind the gap! |
| Q49679461 | Pyoderma Gangrenosum-associated Granulomatosis with Polyangitis: A Case Report and Literature Review |
| Q26751357 | Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q39117005 | Rituximab in ANCA-Associated Vasculitis |
| Q35228543 | Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement |
| Q38489783 | Role of therapeutic plasmapheresis in ANCA-associated vasculitis. |
| Q50076914 | S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis |
| Q50086076 | S1 guidelines on diagnostics and treatment of ANCA-associated vasculitis |
| Q37647438 | The Effects of Plasma Exchange on Severe Vasculitis with Diffuse Alveolar Hemorrhage. |
| Q47107377 | The European Vasculitis Society 2016 Meeting Report |
| Q87954665 | The treatment of ANCA-associated rapidly-progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis |
| Q59160663 | Therapeutic Management of Pediatric Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis |
| Q64260727 | Therapeutic Plasma Exchange in Renal Disorders |
| Q91991945 | Therapeutic plasma exchange - A brief review of indications, urgency, schedule, and technical aspects |
| Q53695276 | Therapeutic plasma exchange for refractory SLE: A comparison of outcomes between different sub-phenotypes. |
| Q47553136 | Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis |
| Q38965278 | Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective. |
| Q40867645 | Therapy of ANCA-associated vasculitis with severe renal manifestation under routine conditions |
| Q41476938 | Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy |
| Q38389839 | Twenty-five years of European Union collaboration in ANCA-associated vasculitis research |
| Q28069897 | Updates in ANCA-associated vasculitis |
| Q91962322 | Use of Plasmapheresis and Immunosuppressants to Treat Diffuse Alveolar Hemorrhage in a Patient with Granulomatosis with Polyangiitis |
| Q39215583 | Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US. |
| Q53060772 | What are the Newer Applications for Therapeutic Apheresis in Nephrology?: Clinical Application of Therapeutic Apheresis in Nephrology in Japan. |
| Q28259540 | What is new in the management of rapidly progressive glomerulonephritis? |
| Q51733829 | [Role of plasmapheresis and immunoadsorption in salvage therapy of rheumatological diseases]. |
| Q93111593 | [What are the indications for rescue procedures? : Systemic rheumatic diseases in the intensive care unit] |